Instil Bio, Inc. Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High
Instil Bio, Inc. (TIL) had Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High of $14.80 million as of 2020-03-31, per its 10-Q filed 2021-05-13.
Discontinued › Notes › Business Combination, Asset Acquisition, Transaction between Entities under Common Control, and Joint Venture Formation
us-gaap:BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh · last filed 2021-05-13
- 2020-03-31: Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High $14.80M.
| Period end | Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High |
|---|---|
| 2020-03-31 | $14.80M 10-Q · filed 2021-05-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Tevogen Inc. (TVGN) | United States | $0.049B | |
| LeonaBio, Inc. (LONA) | United States | $0.047B | -0.61 |
| Metagenomi Therapeutics, Inc. (MGX) | United States | $0.044B | -0.48 |
| Scilex Holding Co (SCLX) | United States | $0.042B | -0.14 |
| Inmune Bio, Inc. (INMB) | United States | $0.056B | -2.48 |
| ImageneBio, Inc. (IMA) | United States | $0.056B | -1.31 |
| BioAtla, Inc. (BCAB) | United States | $0.058B | -0.21 |
| EXOZYMES INC. (EXOZ) | United States | $0.058B | |
| MiNK Therapeutics, Inc. (INKT) | United States | $0.063B | -5.37 |
| aTYR PHARMA INC (ATYR) | United States | $0.033B | -0.98 |